
CAS 893772-67-3
:Fórmula:C12H7F3N4O2
InChI:InChI=1S/C12H7F3N4O2/c1-19-7-3-2-5(12(13,14)15)4-6(7)16-8-9(19)17-11(21)18-10(8)20/h2-4H,1H3,(H,18,20,21)
Chave InChI:KCDITQBGZLRTBX-UHFFFAOYSA-N
SMILES:CN1C2=C(C=C(C=C2)C(F)(F)F)N=C3C1=NC(=O)NC3=O
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Foram encontrados 4 produtos.
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
10-Methyl-7-(trifluoromethyl)benzo[g]pteridine-2,4(3h,10h)-dione
CAS:10-Methyl-7-(trifluoromethyl)benzo[g]pteridine-2,4(3h,10h)-dioneFórmula:C12H7F3N4O2Pureza:97%Peso molecular:296.210-methyl-7-(trifluoromethyl)benzo[g]pteridine-2,4(3H,10H)-dione
CAS:Fórmula:C12H7F3N4O2Pureza:97%Cor e Forma:SolidPeso molecular:296.2048PLK1-IN-9
CAS:PLK1-IN-9 (Compound M2), a polo-like kinase 1 (PLK1) inhibitor, targets the PLK proteins modified with peptides 1010pT, cdc25c, and PBIP, exhibiting IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines including HeLa, HL60, SNU387/499, and HepG2, demonstrating cytotoxic effects and inducing apoptosis. Additionally, PLK1-IN-9 has been shown to suppress tumor growth in a HepG2 xenograft mouse model.Fórmula:C12H7F3N4O2Peso molecular:296.204810-Methyl-7-(trifluoromethyl)benzo[g]pteridine-2,4(3H,10H)-dione
CAS:Produto ControladoFórmula:C12H7F3N4O2Cor e Forma:NeatPeso molecular:296.205




